Apricus Biosciences, Inc.
Apricus Biosciences to Present at the 28th Annual ROTH Conference
SAN DIEGO, 2016-03-08 13:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Barbara Troupin, M.D., Chief Medical Officer, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016, at 7:30 a.m. Pacific Time. The conference will be held at The Ritz Carlton, Dana Point, CA. Dr. Troupin will provide an update on Vitaros®*, the Company's topical treatment for erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.
A live audio webcast of the presentation can be accessed via the Investor Relations section of the Company's website atwww.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon, and plans to conduct additional clinical trials in patients with Raynaud’s phenomenon secondary to scleroderma. Apricus’ lead commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus’ second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visithttp://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
VistaJet Ltd22.11.2017 11:40 | pressemeddelelse
VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller
Nasdaq22.11.2017 10:03 | pressemeddelelse
Nasdaq to Deliver Blockchain e-Voting Solution to Strate
Oxford Immunotec21.11.2017 15:16 | pressemeddelelse
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
Crown Bioscience Inc.21.11.2017 14:02 | pressemeddelelse
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
OmniComm Systems Inc.21.11.2017 14:02 | pressemeddelelse
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics
Nasdaq21.11.2017 11:32 | pressemeddelelse
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum